Patient-Derived Organoids for Drug Screening and Development
Dr. Sylvia Boj discusses the biology underlying organoids, how it contributes to their relevance as model systems and their use in drug discovery and precision medicine. During her postdoctoral fellowship in the lab of Dr. Hans Clevers, Dr. Boj generated and characterized a novel system for modeling pancreatic ductal adenocarcinoma using organoids grown from isolated pancreatic ducts. Now a Scientific Director at the Foundation Hubrecht Organoid Technology (HUB), Dr. Boj is involved in the characterization of organoid model systems with the goal of developing novel platforms for drug discovery. This approach has been successfully used at the HUB using patient-derived organoids to screen treatment outcomes in Cystic Fibrosis.
Publish Date: July 25, 2017
Views: 1113
Related Multimedia
-
3:19Intestinal Organoid Culture with IntestiCult™
Publish Date: January 22, 2015 Views: 2134 -
1:03:40From Stem Cells to Organoids: Modeling the Gastrointestinal Tract
Publish Date: June 20, 2014 Views: 906 -
56:31Modeling Human Gastrointestinal Development and Disease Using Pluripotent Stem Cells
Publish Date: March 06, 2017 Views: 645
Explore Our Products
-
IntestiCult™ Organoid Growth Medium (Human)
Cell culture medium for establishment and maintenance of human intestinal organoids -
STEMdiff™ Intestinal Organoid Kit
Serum-free medium kit for establishment and maintenance of human intestinal organoids from hPSCs